#Singapore #CRO #Emerald Clinical Trials #Michael Stibilj

Emerald Clinical Trials Appoints Michael Stibilj as New CEO

Emerald Clinical Trials, a premier clinical research organization (CRO) based in Asia-Pacific, has recently announced a significant leadership change by appointing Michael Stibilj as its new Chief Executive Officer, effective October 1, 2026. This strategic appointment signals the commencement of an exciting growth phase for the company, which aims to enhance its position in the global clinical research industry.

About Michael Stibilj

Michael Stibilj brings over 30 years of extensive experience in the global CRO arena. His previous tenure spanned six years as Chief Operating Officer at Novotech, and prior to that, he held the position of CEO at PPC Group for three years. Stibilj's extensive career also includes a remarkable 22-year stint at IQVIA, where he excelled in various regional and global leadership roles. His background reflects a robust operational expertise and a history of navigating complex transformations, driving substantial revenue growth, and establishing market leadership, particularly across the Asia-Pacific region, including in major markets like China, Singapore, and Australia.

The decision to elevate Stibilj to the CEO role comes on the heels of a transformative year for Emerald Clinical, characterized by the acquisition of Hongyi Clinical Development Services. This merger has established a uniquely poised clinical development platform comprising over 1,000 professionals spread across more than 40 countries and 70 locations. The combined entity is well-equipped to support sponsors throughout the clinical trial process from first-in-human studies to post-marketing efforts globally, notably across Asia-Pacific, Europe, and the Americas.

A Vision for the Future

In a statement regarding his new role, Stibilj expressed his enthusiasm for leading Emerald Clinical into its next chapter. He noted, "Michael is the right leader for Emerald Clinical's next chapter of growth...He combines proven operational strength, a global perspective, and deep Asia-Pacific experience with a track record of taking businesses to the next level." Sean Carney, Chairman of the Board, commended Stibilj's extensive experience and vision for driving the company forward.

Stibilj emphasized that the outlook for the clinical research industry is exceptionally promising. He remarked, "The future of clinical research will be shaped by the application of technological advances at the intersection of global reach and Asia-Pacific depth — and no company sits more squarely at that intersection than Emerald Clinical." This statement not only underscores the company's strategic positioning but also its intent to leverage innovation as a cornerstone of its growth strategy.

Commitment to Excellence

Emerald Clinical's commitment to quality and transparency remains a priority as the organization seeks to enhance its service offerings. Stibilj stated, “Our commitment to our people and customers is clear. High-quality delivery, speed, and transparency in everything we do are paramount.” His proactive approach is aimed at fostering a collaborative and dynamic organizational environment that resonates strongly with the current momentum within the industry.

As the clinical trial landscape continues to evolve, Stibilj's leadership and vision will be pivotal in driving Emerald Clinical towards achieving heightened levels of global competitiveness. The collective expertise within Emerald Clinical's ranks, along with its expansive network, positions the organization well to make a significant impact in clinical development across various therapeutic areas.

About Emerald Clinical Trials

Emerald Clinical Trials has established itself as a reputable global, full-service CRO with over 25 years of experience, partnering with over 160 biotechnology companies and 15 of the top 20 pharmaceutical firms globally. Headquartered in Singapore, the organization is staffed by a diverse team of professionals across 40+ countries and operates a collaborative network that spans 70+ locations. Emerald Clinical is known for delivering comprehensive Phase I–IV clinical solutions and real-world evidence across several specialties, including oncology, renal, cardiometabolic, autoimmune, and early-phase development. In China, the company operates under the name Emerald Clinical 弘翼临床.

For further information, please visit their official website at www.emeraldclinical.com.